Cilostazol in Acute Ischemic Stroke Treatment (CAIST)

Phase 4 Completed 468 enrolled Korea Otsuka Pharmaceutical Co., Ltd. Korea Otsuka International Asia Arab · collab Seoul National University Boramae Hospital · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to study efficacy and safety of cilostazol use in patients with acute ischemic stroke.

Timeline

Start: 2006-01
Primary completion: —
Completion: 2008-09

Outcome

Met primary endpoint

paper The primary endpoint was achieved in 76% (173/228) of those randomized to cilostazol and in 75% (165/219) assigned to aspirin PMID 21613787 ↗

paper which supported the pre-specified non-inferiority of cilostazol to aspirin (95% CI of proportion difference: -6.15 to 7.22%, p = 0.0004). PMID 21613787 ↗

Publications

Lee YS, Bae HJ, Kang DW, Lee SH, Yu K, Park JM, Cho YJ, Hong KS, Kim DE, Kwon SU, Lee KB, Rha JH, Koo J, Han MG, Lee SJ, Lee JH, Jung SW, Lee BC, Kim JS. Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. Cerebrovasc Dis. 2011;32(1):65-71. doi: 10.1159/000327036. Epub 2011 May 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aspirin	Small molecule	300 mg	—
Subject	Cilostazol	Small molecule	200 mg	—